Granuloma Annulare: A Clinical Update
Current Dermatology Reports,
Год журнала:
2024,
Номер
13(3), С. 183 - 197
Опубликована: Май 22, 2024
Abstract
Purpose
of
Review
Granuloma
annulare
(GA)
is
a
benign,
inflammatory
granulomatous
skin
condition
that
can
present
as
localized,
disseminated,
subcutaneous,
perforating
and
few
other
less
prevalent
subtypes.
While
GA
may
manifest
self-limited
condition,
its
distinctive
feature
mimicking
diseases,
difficulties
in
distinguishing
between
subtypes,
add
complexity
to
the
diagnostic
process.
This
review
was
conducted
evaluate
latest
published
studies
outline
options
for
treatment.
Recent
Findings
Multiple
treatment
modalities
have
been
reported,
including
topical
oral
along
with
many
procedures,
wherefrom
phototherapy
remains
most
well-studied
option.
Recently
new
identified
Th1,
Th2,
JAK-
STAT
pathways
dysregulation
lesions,
subsequently,
promising
effects
reported
targeting
therapy
GA.
Summary
There
still
no
gold
standard
clinical
management
Evidence-based
recommendations
derived
from
randomized
control
trials
are
scarce,
since
majority
research
confined
case
reports,
series,
singular
retrospective
studies.
Therapeutic
approach
vary
depending
on
subtype
GA,
necessitating
individualization
based
patients
preferences,
possible
side
risk-benefit
ratio.
Язык: Английский
Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis
JID Innovations,
Год журнала:
2023,
Номер
3(5), С. 100220 - 100220
Опубликована: Авг. 9, 2023
Inflammatory
cutaneous
granulomatous
diseases,
including
granuloma
annulare,
sarcoidosis,
and
necrobiosis
lipoidica,
are
distinct
diseases
unified
by
the
hallmark
of
macrophage
accumulation
activation
in
skin.
There
currently
no
Food
Drug
Administration–approved
therapies
for
these
conditions
except
prednisone
repository
corticotropin
injection
pulmonary
sarcoidosis.
Treatment
has
generally
been
guided
low-quality
evidence
may
involve
broadly
immunomodulatory
medications.
Development
new
treatments
part
limited
an
incomplete
understanding
disease
pathogenesis.
Recently,
there
substantial
progress
better
molecular
pathogenesis
disorders,
opening
door
therapeutic
innovation.
Likewise,
reported
outcomes
treatment
with
immunologically
targeted
offer
insights
into
In
this
systematic
review,
we
summarize
deciphering
pathomechanisms
disorders
discuss
context
emerging
on
use
molecularly
diseases.
Язык: Английский